A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Impaired long-term outcomes of patients with schizophrenia spectrum disorder after coronary artery bypass surgery: nationwide case-control study




TekijätKallio Mika, Korkeila Jyrki, Malmberg Markus, Gunn Jarmo, Rautava Päivi, Korhonen Päivi, Kytö Ville

KustantajaCAMBRIDGE UNIV PRESS

Julkaisuvuosi2022

JournalBJPsych Open

Tietokannassa oleva lehden nimiBJPSYCH OPEN

Lehden akronyymiBJPSYCH OPEN

Artikkelin numeroPII S2056472422000102

Vuosikerta8

Numero2

Sivujen määrä7

ISSN2056-4724

DOIhttps://doi.org/10.1192/bjo.2022.10

Verkko-osoitehttps://www.cambridge.org/core/journals/bjpsych-open/article/impaired-longterm-outcomes-of-patients-with-schizophrenia-spectrum-disorder-after-coronary-artery-bypass-surgery-nationwide-casecontrol-study/B016805D2C7D933F553A32344D4BA76E

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/69091760


Tiivistelmä

Background: Patients with schizophrenia spectrum disorder have increased risk of coronary artery disease.

Aims: To investigate long-term outcomes of patients with schizophrenia spectrum disorder and coronary artery disease after coronary artery bypass grafting surgery (CABG).

Method: Data from patients with schizophrenia spectrum disorder (n = 126) were retrospectively compared with propensity-matched (1:20) control patients without schizophrenia spectrum disorder (n = 2520) in a multicentre study in Finland. All patients were treated with CABG. The median follow-up was 7.1 years. The primary outcome was all-cause mortality.

Results: Patients with diagnosed schizophrenia spectrum disorder had an elevated risk of 10-year mortality after CABG, compared with control patients (42.7 v. 30.3%; hazard ratio 1.56; 95% CI 1.13-2.17; P = 0.008). Schizophrenia spectrum diagnosis was associated with a higher risk of major adverse cardiovascular events during follow-up (49.9 v. 32.6%, subdistribution hazard ratio 1.59; 95% CI 1.18-2.15; P = 0.003). Myocardial infarction (subdistribution hazard ratio 1.86; P = 0.003) and cardiovascular mortality (subdistribution hazard ratio 1.65; P = 0.017) were more frequent in patients with versus those without schizophrenia spectrum disorder, but there was no difference for stroke. Psychiatric ward admission, antipsychotic medication, antidepressant use and benzodiazepine use before CABG were not associated with outcome differences. After CABG, patients with schizophrenia spectrum disorder received statin therapy less often and had lower doses; the use of other cardiovascular medications was similar between schizophrenia spectrum and control groups.

Conclusions: Patients with schizophrenia spectrum disorder have higher long-term risks of death and major adverse cardiovascular events after CABG. The results underline the vulnerability of these patients and highlight the importance of intensive secondary prevention and risk factor optimisation.


Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.





Last updated on 2024-26-11 at 11:51